China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for ...

Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the EADV 2024 Congress ...

China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on September ...

Though INCY's performance in the year so far has been good, increasing competition for Jakafi is a concern. We advise ...

(NEW YORK) — The U.S. Food and Drug Administration granted approval on Monday for Opzelura, which is the first topical JAK inhibitor cream for the treatment of vitiligo for people 12 and older.

Last year, Incyte became the first pharma company to get approval for a drug that can re-pigment the skin in vitiligo – topical JAK1/JAK2 inhibitor Opzelura (ruxolitinib) – for patients whose ...

It is facing competition in the category from non-steroid drugs like Incyte’s JAK inhibitor Opzelura (ruxolitinib ... and its second indication vitiligo. Other potential rivals include Dermavant ...

Vitiligo is believed to be an autoimmune condition where the body attacks its own healthy melanin-producing skin cells by mistake. It may be hereditary or triggered by a particular event like ...

Keywords: Vitiligo, Artificial Intelligence, Novel Therapies Dermatology, Patient Care, Clinical Research, Diagnostic Tools, Treatment Outcomes, AI in Medicine, Skin Disorders Important Note: All ...

Vitiligo causes patches of skin with lost pigment, but it can also raise your risk of eye and skin damage from UV rays. Find out how new and old treatments may work for your vitiligo.